Cysteine

Where the papers sit

10 papers from the last 6 months study cysteine directly · updated from PubMed 1 Nov 2026

• Biological Assay Development

  Reactive protein-targeting and screening strategies dominate early discovery of inhibitors and diagnostic assays. Covalent compounds target chikungunya nsP2 and ATG4B, while tanespimycin suppresses SARS-CoV-2 main protease and reactive metallo-scaffolds enable proteome-wide target identification. CRISPR/Cas12a detection and QSAR-guided antitrypanosomal design broaden the toolkit beyond direct inhibitor testing. The work favors rapid, structure-informed screening, but does not establish one shared drug class or clinical endpoint.

  6 papers · 60%

• Sulfur Amino Acid Biology

  Oxidation and metabolism of sulfur-containing amino acids link protein stability to clinical prognosis. EvoMut uses methionine, tryptophan, histidine and arginine substitutions to engineer oxidative stability, whereas patient data associate homocysteine, cysteine and methionine with 90-day outcome after intracerebral hemorrhage. Regression and biochemical analysis recur, but the computational and clinical aims remain distinct. The cluster supports design and association questions rather than a shared therapeutic direction.

  2 papers · 20%

• Copper–Cysteine Antibacterial Biology

  Copper–cysteine chemistry is being connected to antibacterial activity at both material and microbial levels. Copper-cysteine nanoparticles show chirality-dependent killing and cytocompatibility in silk sutures designed to improve wound healing. In Mycobacterium tuberculosis, inducible CysK2-mediated cysteine synthesis supports copper resistance, shifting attention toward bacterial adaptation. Together, the work balances exploiting copper toxicity against understanding thiol-based resistance mechanisms, with in vivo efficacy and durability still open.

  2 papers · 20%